Group 1 - The core point of the article is that MicroPort Cardiac Rhythm Management (微创心通-B) has seen its stock price increase by over 6% following the announcement of a significant regulatory milestone for its new generation implantable cardioverter-defibrillator (ICD) [1] - As of the time of reporting, the stock price rose by 6.33% to HKD 0.84, with a trading volume of HKD 8.5992 million [1] - The National Medical Products Administration (NMPA) has indicated its intention to approve the TILEN/EYLEN ICD for entry into the special review process, which is part of the NMPA's green channel for innovative medical devices [1] Group 2 - The TILEN/EYLEN ICD is expected to be the first domestically approved ICD with independent intellectual property rights that is safe for use under magnetic resonance conditions [1]